Major Pharmaceuticals Recalls Levothyroxine Sodium Tablets Over Subpotency
Major Pharmaceuticals is recalling Levothyroxine Sodium Tablets, 150 mcg, lot N02167, due to subpotent drug concerns. The recall affects nationwide distribution in the USA.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall of a prescription drug (levothyroxine sodium) due to subpotency, which falls under the rubric criterion for FDA Class II recalls. The medication is used for thyroid hormone replacement, and subpotency could compromise treatment efficacy.
Plain-English summary
Major Pharmaceuticals is voluntarily recalling Levothyroxine Sodium Tablets, USP, 150 mcg (0.0150 mg), packaged in 100-tablet cartons (10 x 10 unit dose blisters), NDC 0904-6956-61. The affected product is identified by lot number N02167 with an expiration date of July 2026.
The reason for the recall is subpotent drug, meaning the tablets may not contain the full labeled amount of levothyroxine sodium. Levothyroxine is a prescription medication used to treat thyroid hormone deficiency, and subpotency could reduce its effectiveness.
The recall was initiated on July 13, 2026, and is classified as a Class II recall by the FDA. The product was distributed nationwide in the USA. The recall is being conducted voluntarily by the firm.
Consumers and healthcare providers should not use the affected lot. Patients taking levothyroxine should contact their healthcare provider to discuss alternative treatment options. The recalling firm has notified distributors and customers of the recall.
The recalled product
- Product
- LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)
- Brand
- LEVOTHYROXINE SODIUM
- Manufacturer
- Major Pharmaceuticals
- Hazard
- subpotent-drug
- treatment-failure
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: N02167
- Exp. Date 07/2026
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LEVOTHYROXINE SODIUM
- HighLevothyroxine Sodium Tablets Recalled for Subpotency by Major Pharmaceuticals
FDA (Drugs) · 2026-07-29
- SevereLevothyroxine Sodium Tablets Recalled for Subpotency Nationwide
FDA (Drugs) · 2026-07-29
- HighLevothyroxine Sodium Tablets Recalled Due to Subpotent Drug Concerns
FDA (Drugs) · 2026-07-29
- SevereMajor Pharmaceuticals Recalls Levothyroxine Sodium Tablets Over Subpotency
FDA (Drugs) · 2026-07-29
- SevereLevothyroxine Sodium Tablets Recalled for Subpotency
FDA (Drugs) · 2026-07-29
Same category
- SevereMajor Pharmaceuticals Recalls Levothyroxine Sodium Tablets Over Subpotency
FDA (Drugs) · 2026-07-29
- HighLevothyroxine Sodium Tablets Recalled Due to Subpotent Drug Concerns
FDA (Drugs) · 2026-07-29
- HighNaropin Injection Recall Over Particulate Matter Contamination
FDA (Drugs) · 2026-07-29
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
- HighXylocaine Injection Recall Due to Hair Contamination
FDA (Drugs) · 2026-07-29